NLG 802

Drug Profile

NLG 802

Alternative Names: Indoleamine 2,3-Dioxygenase (IDO) Inhibitor; NLG-802

Latest Information Update: 28 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lankenau Institute for Medical Research
  • Developer NewLink Genetics Corporation
  • Class Antineoplastics
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Prodrug activators; Tryptophan oxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 29 Jun 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Recurrent) in USA (PO) (NCT03164603)
  • 25 May 2017 NewLink Genetics Corporation plans a phase I trial for Solid tumours(Late-stage disease) in USA (NCT03164603)
  • 04 May 2017 NewLink Genetics plans clinical trials of NLG 802 by the end of third quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top